Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Capital Expenditures: 2015-2023

Historic Capital Expenditures for Spyre Therapeutics (SYRE) over the last 7 years, with Sep 2023 value amounting to -$2.1 million.

  • Spyre Therapeutics' Capital Expenditures fell 206800.00% to -$2.1 million in Q3 2023 from the same period last year, while for Sep 2023 it was -$1.9 million, marking a year-over-year decrease of 1302.48%. This contributed to the annual value of $38,000 for FY2022, which is 93.37% down from last year.
  • According to the latest figures from Q3 2023, Spyre Therapeutics' Capital Expenditures is -$2.1 million, which was down 206,800.00% from $1,000 recorded in Q3 2022.
  • In the past 5 years, Spyre Therapeutics' Capital Expenditures registered a high of $1.4 million during Q1 2020, and its lowest value of -$2.1 million during Q3 2023.
  • For the 3-year period, Spyre Therapeutics' Capital Expenditures averaged around -$242,667, with its median value being $33,500 (2021).
  • Per our database at Business Quant, Spyre Therapeutics' Capital Expenditures spiked by 2,224.56% in 2020 and then plummeted by 206,800.00% in 2023.
  • Spyre Therapeutics' Capital Expenditures (Quarterly) stood at $1.2 million in 2019, then dropped by 14.82% to $1.0 million in 2020, then tumbled by 83.57% to $93,000 in 2021, then slumped by 98.92% to $1,000 in 2022, then plummeted by 206,800.00% to -$2.1 million in 2023.
  • Its Capital Expenditures stands at -$2.1 million for Q3 2023, versus $1,000 for Q3 2022 and $37,000 for Q1 2022.